Method for determining the abundance of highly active heparin with respect to porcine small intestinal mucosa heparin IIa
By employing techniques such as the PowerSoil reagent kit, PCR amplification, Illumina NovaSeq 6000 sequencing, and the LEfSe algorithm, the problems of long detection cycles and inaccurate results in the detection of highly active heparin against porcine small intestinal mucosa in existing technologies have been solved. This has enabled high-sensitivity and low-cost heparin abundance determination, improving the quality of heparin products and controlling procurement costs.
Patent Information
- Authority / Receiving Office
- CN Β· China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- HUANGCHUAN PENGSHENG ANIMAL PROD CO LTD
- Filing Date
- 2026-02-24
- Publication Date
- 2026-07-14
AI Technical Summary
Existing technologies for detecting highly active heparin against IIa in porcine small intestinal mucosa suffer from problems such as long experimental cycles, large error in results, inaccurate detection results, and complex processes, leading to fluctuations in heparin product quality and high procurement costs.
Porcine small intestinal mucosal cells were lysed using the PowerSoil kit, followed by PCR amplification, high-throughput sequencing using an Illumina NovaSeq 6000 sequencer, noise reduction using the DADA2 workflow, annotation from the Greengenes database, and screening for differentially expressed microbiota using the LEfSe algorithm. A random forest model was then used to predict heparin activity, achieving high sensitivity and accuracy in detection.
This method enables the determination of high-anti-IIa heparin abundance in porcine small intestinal mucosa with short detection time, low cost, and accurate results. It is suitable for multi-point sampling studies and improves the stability of heparin product quality and control of procurement costs.